Dr. Oliver Peoples, Chief Scientific Officer of Metabolix, commented, "The experience and knowledge we have gained during our tobacco field trial is laying the groundwork for planning and permitting activities for field trials in bioengineered, non-food oilseed and biomass crops producing PHA. We believe that our crop programs offer a number of commercialization options and hold significant potential. We are excited to continue to push this technology forward and believe it will ultimately support a diverse array of bioengineered, environmentally conscious and economically viable alternatives to petroleum-based products."
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel(TM), a family of high performance bioplastics which are biobased and biodegradable alternatives to many petroleum-based plastics. Metabolix is also developing a proprietary platform technology for co-producing plastics, chemicals and energy, from crops such as switchgrass, oilseeds and sugarcane.
For more information, please visit www.metabolix.com. (MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for Metabolix research and development programs, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports on Form 10-Q. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.
SOURCE: Metabolix, Inc.
ICR Media: Matt Lindberg, 203-682-8214 matthew.lindberg@icrinc.com or Brian Ruby, 203-682-8268 brian.ruby@icrinc.com or Investors: James Palczynski, 203-682-8229 james.palczynski@icrinc.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index